MALT1 Modulator Compounds for Autoimmune and Cancer Treatment

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current therapies are inadequate for effectively modulating MALT1 activity to treat autoimmune and inflammatory diseases, disorders, or conditions, or cancers such as MALT lymphoma and ABC-DLBCL.

Innovation Solution

Development of compounds represented by Formulas (I), (Ia), (Ib), and (Ic), which act as MALT1 modulators, including stereoisomers and pharmaceutically acceptable salts, to regulate MALT1 activity and provide therapeutic benefits.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current therapies are used to treat autoimmune and inflammatory diseases or cancers, then treatment is provided, but the therapies are inadequate for effectively modulating MALT1 activity

Engineering Contradiction:

Improveeffectiveness of MALT1 modulationVSAvoidability to treat MALT1-driven pathologies

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent applies parameter changes by developing compounds with specific molecular structures (Formulas I, Ia, Ib, Ic) that target MALT1 activity. The compounds feature variable substituents (R1, R2, R3, R1a, R2a, Z, RA, m, n) that can be modified to optimize MALT1 modulation effectiveness, directly addressing the inadequacy of current therapies in effectively modulating MALT1 activity

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent segments the therapeutic approach by creating distinct compound series (Formulas I, Ia, Ib, Ic) with different structural characteristics. Each formula represents a segmented approach to MALT1 modulation, allowing selective optimization for different MALT1-driven pathologies such as autoimmune diseases, inflammatory conditions, or cancers

Inventive Principle:

Principle #1Segmentation

2Reliability

If targeted MALT1 modulation is achieved through new compounds, then therapeutic effectiveness improves, but compound structure complexity increases

Engineering Contradiction:

Improvetherapeutic effectivenessVSAvoidcompound structure complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent manages complexity by systematically varying molecular parameters within defined ranges. The core structure remains consistent across Formulas I, Ia, Ib, and Ic, with controlled modifications at specific positions (R1, R2, R3, etc.), allowing therapeutic optimization without excessive structural complexity

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent creates universal compound scaffolds that can function across multiple MALT1-driven pathologies. The core molecular framework in all four formulas serves as a universal platform that can be adapted for treating autoimmune diseases, inflammatory conditions, and cancers, reducing the need for entirely separate complex structures for each indication

Inventive Principle:

Principle #6Universality (Multi-functionality)

Data Source

PatentUS20250326738A1MALT1 Modulators and Uses Thereof

Publication Date: 2025.10.23 RAREFIED BIOSCIENCES INC

AI summary

Provided herein are compounds, compositions, and methods useful for modulating MALT1 and for treating related diseases, disorders, and conditions.